Lassen Therapeutics is developing novel antibody treatments for fibro-inflammatory diseases and cancer, focusing on the IL-11R receptor (LASN01) and interleukin-18 binding proteins.
The CFTR protein is an ion channel mainly used to regulate the transepithelial movement of anions in mucus secretion tissues, thereby coordinating the balance of salt and fluid levels in mucus secretions.
This article summarized the latest R&D progress of Tioconazole, the Mechanism of Action for Tioconazole, and the drug target R&D trends for Tioconazole.
EyePoint Pharmaceuticals, Inc., a company focused on improving life quality for severe eye condition patients, has revealed promising safety data for its key product candidate EYP-1901.